Polymer-drug conjugates: recent progress on administration routes

Bibliography

• Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed 2006;45:1198-215
   PubMed Web of Science ®Google Scholar
• Jatzkewitz H. Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z Naturforsch 1955;10b:2731
   Google Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60
   PubMed Web of Science ®Google Scholar
• Regelson W. Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J Bioact Compat Polym 1986;1:84-106
   Google Scholar
• Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975;51:135-53
   Google Scholar
• Maeda H, Wu J, Matsumura Y, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
   PubMed Web of Science ®Google Scholar
• Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Del Rev 2009;61:1220-31
   PubMed Web of Science ®Google Scholar
• Zempsky WT. Alternative routes of drug administration–advantages and disadvantages (subject review). Pediatrics 1998;101:730-1
   PubMed Web of Science ®Google Scholar
• Veronese FM. PEGylated protein drugs: basic science and clinical applications. Birkhäuser Verlag, Basel; 2009
   Google Scholar
• Kopeček J, Kopečková P. Design of polymer–drug conjugates. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim; 2012
   Google Scholar
• Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012;161:446-60
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese F. Polymer-drug conjugation, recent achievements and general strategies. Prog Poly Sci 2007;32:933-61
   Web of Science ®Google Scholar
• Kopeček J. Polymer–drug conjugates: origins, progress to date and future directions. Adv Drug Del Rev 2013;65:49-59
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2009;6:688-701
   Google Scholar
• Jain RK. Barriers to drug-delivery in solid tumors. Sci Am 1994;271:58-65
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13
   PubMed Web of Science ®Google Scholar
• Seymour LW, Duncan R, Strohalm J, et al. Effect of molecular weight (MW) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J Biomed Mat Res 1987;21:1341-58
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995;84:349-54
   PubMed Web of Science ®Google Scholar
• Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-16
   PubMed Web of Science ®Google Scholar
• Pang X, Du HL, Zhang HQ, et al. Polymer–drug conjugates: present state of play and future perspectives. Drug Discov Today 2013;18:1316-22
   PubMed Web of Science ®Google Scholar
• Duncan R, Richardson SCW. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges in preparation. Mol Pharm 2012;9:2380-402
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 2013;65:60-70
   PubMed Web of Science ®Google Scholar
• Vercauteren R, Bruneel D, Schacht E, et al. Effect of the chemical modification of dextran on the degradation by dextranases. J Bioact Compat Polym 1990;5:4-15
   Google Scholar
• Danhauser-Ried S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993;11:187-95
   PubMed Web of Science ®Google Scholar
• Soepenberg O, de Jonge MJ, Sparreboom A, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005;11:703-11
   PubMed Web of Science ®Google Scholar
• Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. Int J Pharm 1988;87:787-96
   Google Scholar
• Terwogt JM, Schellens JH, Huinink WW, et al. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 1999;25:83-101
   PubMed Web of Science ®Google Scholar
• Kruijtzer C, Beijnen J, Schellens J. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-30
   PubMed Web of Science ®Google Scholar
• Weinberger S, Martinez J. Characterization of hydrolysis of [leu]enkephalin and D-ala2-[L-leu] enkephalin in rat plasma. J Pharmacol Exp Ther 1988;247:129-35
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today 2013;18:25-34
   PubMed Web of Science ®Google Scholar
• Thanki K, Gangwal RP, Sangamwar AT, et al. Oral delicery of anticancer drugs: challenges and opportunities. J Control Release 2013;170:15-40
   PubMed Web of Science ®Google Scholar
• Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154:1542-50
   PubMed Web of Science ®Google Scholar
• Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 2002;4:459-66
   PubMedGoogle Scholar
• Youn YS, Jung JY, Oh SH, et al. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006;114:334-42
   PubMed Web of Science ®Google Scholar
• Nojima Y, Suzuki Y, Iguchi K, et al. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug Chem 2008;19:2253-9
   PubMed Web of Science ®Google Scholar
• Anwar M, Warsi MH, Mallick N, et al. Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci 2011;44:241-9
   PubMed Web of Science ®Google Scholar
• Lee E, Kim H, Lee IH, et al. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009;140:79-85
   PubMed Web of Science ®Google Scholar
• Lee E, Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51:6442-9
   PubMed Web of Science ®Google Scholar
• Lee E, Lee J, Jon S. A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan. Bioconjug Chem 2010;21:1720-3
   PubMed Web of Science ®Google Scholar
• Sakthivel T, Toth I, Florence AT. Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration. Int J Pharm 1999;183:51-5
   PubMed Web of Science ®Google Scholar
• Wiwattanapatapee R, Carreno-Gomez B, Malik N, et al. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000;17:991-8
   PubMed Web of Science ®Google Scholar
• Lin Y, Fujimori T, Kawaguchi N, et al. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J Control Release 2011;149:21-8
   PubMed Web of Science ®Google Scholar
• Mignani S, Kazzouli SE, Bousmina M, et al. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev 2013;65:1316-30
   PubMed Web of Science ®Google Scholar
• Subedi RK, Oh SY, Chun MK, et al. Recent advances in transdermal drug delivery. Arch Pharm Res 2010;33:339-51
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-24
   PubMed Web of Science ®Google Scholar
• Karande P, Jain A, Ergun K, et al. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc Natl Acad Sci USA 2005;102:4688-93
   PubMed Web of Science ®Google Scholar
• Finnin BC, Morgan TM. Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci 1999;88:955-8
   PubMed Web of Science ®Google Scholar
• Sharma K, Singh V, Arora A. Natural biodegradable polymers as matrices in transdermal drug delivery. Int J Drug Dev Res 2011;3:85-103
   Google Scholar
• Yang Y, Bugno J, Hong S. Nanoscale polymeric penetration enhancers in topical drug delivery. Polym Chem 2013;4:2651-7
   Google Scholar
• Filipowicz A, Wolowiec S. Bioconjugates of PAMAM dendrimers with trans-retinal, pyridoxal, and pyridoxal phosphate. Int J Nanomed 2012;7:4819-28
   PubMed Web of Science ®Google Scholar
• Venuganti VV, Perumal OP. Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration. J Pharm Sci 2008;98:2345-56
   Web of Science ®Google Scholar
• Yang Y, Sunoqrot S, Stowell C, et al. The effect of size, surface charge and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromelecules 2012;13:2154-62
   PubMed Web of Science ®Google Scholar
• Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010;141:2-12
   PubMed Web of Science ®Google Scholar
• Yang JA, Kim ES, Kwon JH, et al. Transdermal delivery of hyaluronic acid-human growth hormone conjugate. Biomaterials 2012;33:5947-54
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70
   PubMed Web of Science ®Google Scholar
• Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009;4:299-319
   PubMed Web of Science ®Google Scholar
• Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-44
   PubMedGoogle Scholar
• Xie Y, Aillon KL, Cai S, et al. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 2010;392:156-63
   PubMed Web of Science ®Google Scholar
• Inapagolla R, Guru BR, Kurtoglu YE, et al. In vivo efficacy of dendrimer-methylprednisolone conjugate formation for the treatment of lung inflammation. Int J Pharm 2010;339:140-7
   Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I. Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
   PubMed Web of Science ®Google Scholar
• Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36
   Web of Science ®Google Scholar
• Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition — what evidence is there? Int J Pharm 2011;406:1-10
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
   PubMed Web of Science ®Google Scholar
• Weiner AL, Gilger BC. Advancements in ocular drug delivery. Vet Ophthalmol 2010;13:395-406
   PubMedGoogle Scholar
• Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res 2009;26:1197-216
   PubMed Web of Science ®Google Scholar
• Spataro G, Malecaze F, Turrin CO, et al. Designing dendrimers for ocular drug delivery. Eur J Med Chem 2010;45:326-34
   PubMed Web of Science ®Google Scholar
• Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33:979-88
   PubMed Web of Science ®Google Scholar
• Shaunak S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004;22:977-84
   PubMed Web of Science ®Google Scholar
• Kyyrönen K, Hume L, Benedetti L, et al. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies. Int J Pharm 1992;80:161-9
   Web of Science ®Google Scholar
• Oh EJ, Choi JS, Kim H, et al. Anti-Flt1 peptide-Hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 2011;32:3115-23
   PubMed Web of Science ®Google Scholar